Fig 1: Changes in MFG-E8 levels in CSF measured by ELISA. The MFG-E8 protein levels at different times after aSAH and in the control cohort. *p < 0.05 compared with the control cohort; #p < 0.05 compared with the day 3 cohort.
Fig 2: The link between MFG-E8 and the changes of GCS. (a) The association between MFG-E8 levels and changes in GCS on the third day. (b) The association between MFG-E8 levels and alterations in GCS on the seventh day.
Fig 3: The relationship between MFG-E8 and changes in GOS. (a) The difference in MFG-E8 levels between cohort 1 and cohort 2 (cohort 1: GOS with elevation on day 7 in contrast with admission and cohort 2: GOS with no elevation on day 7 in contrast with admission). (b) The difference in MFG-E8 levels between cohort 3 and cohort 4 (cohort 3: GOS with elevation on day 9 compared with admission and cohort 4: GOS with no elevation on day 9 compared with admission). (c–f) The correlation between the levels of MFG-E8 on day 3 and the alterations in GOS scores at distinct times following aSAH. *p < 0.05 between cohorts.
Supplier Page from Abcam for Human MFGE8 ELISA Kit